furosemide has been researched along with Ascites in 192 studies
Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.
furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Combined use of furosemide with albumin is an approved therapy to overcome diuretic resistance in treatment of ascites in decompensated chronic liver disease." | 9.34 | Comparative Study of Slow Infusion versus Bolus Doses of Albumin and Furosemide Infusion to Mobilize Refractory Ascites in Decompensated Chronic Liver Disease. ( Jha, A; Kafle, B; Khadga, P; Pathak, R; Thapaliya, S; Yadav, AK, 2020) |
| " Patients without hyperkalemia were administrated 100 mg of spironolactone/day." | 9.22 | High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. ( Demir, M; Dogan, O; Ozer, B; Parlakgumus, A; Serin, E; Yakar, T, 2016) |
| "To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites." | 9.14 | Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. ( Cammà, C; Craxì, A; Di Raimondo, D; Di Sciacca, R; Licata, A; Licata, G; Parrinello, G; Paterna, S; Pinto, A; Tuttolomondo, A, 2009) |
| "Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was -0." | 9.14 | Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. ( Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP, 2010) |
| "Tolvaptan was orally administrated at titrated doses of 15, 30, and 60 mg once daily after breakfast for 3 days at each dose to 18 liver cirrhosis patients with persistent ascites and/or lower limb edema despite receiving oral furosemide at 40 mg/day or higher." | 9.14 | A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. ( Chayama, K; Kaneko, A; Kato, M; Murawaki, Y; Okada, M; Okita, K; Ono, N; Sakaida, I; Sata, M; Yoshihara, H; Yoshihara, N, 2010) |
| "To conduct a randomized, double-blind, placebo-controlled, cross-over study to test the hypothesis that midodrine significantly increases natriuretic response of IV furosemide in non-azotemic cirrhotics with ascites." | 9.14 | The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. ( Chalasani, N; Hamman, M; Jones, D; Kahi, C; Kwo, PY; Misra, VL; Vuppalanchi, R, 2010) |
| " This investigation consists of a double-blind, randomized, placebo-controlled trial aimed at comparing the effects of the selective COX-2 inhibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites." | 9.11 | Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. ( Arroyo, V; Clària, J; Escolar, G; Ginès, P; Jiménez, W; Kent, JD; López-Parra, M; Ruiz-Del-Arbol, L; Vucelic, B, 2005) |
| "The most rational treatment of moderate ascites is spironolactone alone or in combination with furosemide." | 9.10 | Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. ( Cabré, E; Durández, R; Gassull, MA; Granada, ML; Jiménez, JA; Morillas, RM; Pardo, A; Planas, R; Quintero, E; Santos, J, 2003) |
| "These results show that torsemide is as effective and safe as frusemide for long-term treatment of cirrhotic patients with ascites." | 9.09 | Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. ( Abecasis, R; Cobas, S; Guevara, M; Miguez, C; Terg, R, 2001) |
| "To evaluate the pharmacokinetics and pharmacodynamics of furosemide and torasemide in patients with cirrhosis and diuretic resistant ascites." | 9.08 | Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. ( Bernareggi, A; Buzzelli, G; Carloni, V; Chibbaro, G; Cotrozzi, G; Foschi, M; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Melani, L; Quartini, M; Simoni, A; Tommasi, AC, 1996) |
| "Twenty patients with cirrhosis and ascites were randomly divided in two groups to receive 20 mg/die of the new-loop-diuretic torasemide (T), and 50 mg/die of furosemide (F)." | 9.08 | [Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients]. ( Bodini, P; Dizioli, P; Marelli, A; Quinzani, M; Reggiani, A; Tonghini, L, 1997) |
| "In a randomized double-blind trial we compared the effects of torasemide, a new loop diuretic, and furosemide in nonazotemic cirrhotic patients with ascites during a 3-day period in association with potassium canrenoate (200 mg/day) administration." | 9.07 | Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. ( Azzena, G; Buzzelli, G; De Feo, ML; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Meacci, E, 1991) |
| "Nonsteroidal anti-inflammatory drugs (NSAID) suppress prostaglandin-dependent renal blood flow and furosemide-induced diuresis in patients with cirrhosis and ascites." | 9.05 | Sulindac and indomethacin suppress the diuretic action of furosemide in patients with cirrhosis and ascites: evidence that sulindac affects renal prostaglandins. ( Daskalopoulos, G; Gonzalez, M; Katkov, W; Kronborg, I; Laffi, G; Zipser, RD, 1985) |
| " Our group has shown that treatment of patients with diuretic-resistant heart failure with high-dose furosemide plus hypertonic saline is effective and well tolerated, improving symptoms of congestion, reducing plasma levels of markers of neurohormonal and inflammatory activation, decreasing hospital readmission rates, and reducing long-term mortality." | 8.87 | Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites. ( Licata, G; Parrinello, G; Pinto, A; Tuttolomondo, A, 2011) |
| "To evaluate the clinical usefulness of combined furosemide and human albumin for the treatment of diuretic-resistant edema in patients with nephrotic syndrome and cirrhosis." | 8.82 | Combined furosemide and human albumin treatment for diuretic-resistant edema. ( Eisele, G; Elwell, RJ; Spencer, AP, 2003) |
| "Ninety cirrhotic patients with ascites were studied after administration of HSS infusion (n=25) or etilefrine tablets (n=25), or both (n=25) plus standard diuretics therapy (SDT), or SDT alone (n=15)." | 8.12 | Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites. ( Badra, G; El-Haggar, S; El-Said, H; Ibrahim, O; Radwan, H, 2022) |
| "Therapeutic response to tolvaptan was associated with longer survival in cirrhosis patients complicated with ascites." | 7.91 | Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites. ( Kida, Y, 2019) |
| "In human cirrhosis, adrenergic hyperfunction causes proximal tubular fluid retention and contributes to diuretic-resistant ascites, and clonidine, a sympatholytic drug, improves natriuresis in difficult-to-treat ascites." | 7.83 | Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine. ( Aragno, M; Mastrocola, R; Mengozzi, G; Parola, M; Sansoè, G, 2016) |
| "We evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites." | 7.83 | Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites. ( Bellia, C; Ciaccio, M; Clemente, G; Di Bona, D; Di Raimondo, D; Gulotta, E; Maida, C; Pecoraro, R; Pinto, A; Simonetta, I; Tuttolomondo, A; Vassallo, V, 2016) |
| "Tolvaptan is a new drug used for treating ascites induced by liver cirrhosis, and it is covered by health insurance in Japan." | 7.81 | Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites. ( Goto, A; Matsumoto, M; Nakamura, M; Sakaida, I; Terai, S, 2015) |
| "We conducted a retrospective case series of patients admitted for management of ascites who received intravenous furosemide by continuous infusion in ascites management." | 7.78 | Continuous furosemide infusion in the management of ascites. ( Cuthbert, JA; Gupta, S; Rogers, NA, 2012) |
| "To present an atypical case of massive ascites and hydrothorax after leuprolide acetate administration in a down-regulated woman undergoing assisted reproduction." | 7.74 | Massive ascites and hydrothorax after leuprolide acetate administration in a down-regulated woman undergoing assisted reproduction. ( Coppola, F; Ferrari, B; Pezzuto, A, 2007) |
| "To verify prospectively the usefulness of the furosemide-induced natriuresis test in predicting ascites control by medical treatment, 15 stable cirrhotics (9 male) with ascites were studied." | 7.73 | The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusion. ( Apollonio, L; Bartoli, EG; Fabris, C; Pirisi, M; Sereti, K; Toniutto, P, 2006) |
| "In out-patient departments, the measurement of urine sodium 8 hours after administrating 80 mg of intravenous furosemide, will help in differentiating ascites patients with lower treatment response to diuretics." | 7.72 | [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis]. ( Cho, HS; Choi, HS; Hahm, JS; Kim, JB; Kim, YH; Lee, MH; Lee, OY; Park, GT; Shim, SG, 2003) |
| " Recombinant human serum albumin (rHSA) (1 g/kg) significantly decreased the weight of ascites in rats with puromycin aminonucleoside-induced nephropathy." | 7.70 | Effects of recombinant human serum albumin on ascites in rats with puromycin aminonucleoside-induced nephropathy. ( Hanada, S; Maruyama, T; Matsui, T; Nakamura, N; Shintome, M; Tsuchiyama, H; Tsukada, M; Yuki, T, 1998) |
| "We investigated the effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a potent adenosine A1-receptor antagonist, on the nephrotic edema induced by puromycin aminonucleoside (PAN; 100 mg/kg, i." | 7.69 | Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats. ( Karasawa, A; Kusaka, H; Nagashima, K, 1995) |
| "We describe the successful use of combined ascitic-fluid and furosemide infusion as a therapeutic option in the management of massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis in a 30-year-old Nigerian male farmer." | 7.68 | Combined ascitic--fluid and furosemide infusion: a therapeutic option for massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis. ( Ijoma, CK; Nusiem, CA; Nwaneri, O; Offodile, AA; Onuigbo, MA; Onyeagocha, AC; Ozoh, JO, 1991) |
| "Plasma concentrations of atrial natriuretic factor (ANF) and cyclic 3',5'-guanosine monophosphate (cGMP) were measured in 11 cirrhotic patients with ascites, 11 cirrhotic patients without ascites and 15 control subjects." | 7.68 | Atrial natriuretic factor, cyclic 3',5'-guanosine monophosphate and prostaglandin E2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide. ( Jensen, L; Jespersen, B; Pedersen, EB; Sørensen, SS, 1990) |
| "Propranolol hydrochloride is reported to lower portal pressure and inhibit renin secretion in patients with chronic liver disease, actions that might lessen the tendency to ascites formation." | 7.67 | Propranolol in the treatment of cirrhotic ascites. ( Rector, WG; Reynolds, TB, 1984) |
| "In cirrhotic patients low-dose captopril seems to be efficient in the treatment of ascites resistant to diuretics without causing major side effects." | 7.67 | [Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites]. ( Brunkhorst, R; Koch, K; Kühn, K; Schmidt, FW; Wrenger, E, 1989) |
| "Furosemide occasionally causes azotemia in patients with ascites, independently of induced volume depletion." | 7.67 | Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. ( Daskalopoulos, G; Harley, H; Laffi, G; Morgan, T; Pinzani, M; Reynolds, T; Zipser, RD, 1987) |
| "We have studied the efficacy of urea in the treatment of hyponatremia and hydrosaline retention in cirrhotic patients with ascites resistant to diuretics." | 7.67 | Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. ( Cauchie, P; Decaux, G; Delwiche, F; Flamion, B; Mols, P, 1986) |
| "Furosemide, 20 mg, was given intravenously as a bolus to seven patients with cirrhotic ascites and a 10-mg intravenous bolus dose was given to three normal subjects." | 7.66 | Furosemide kinetics in patients with hepatic cirrhosis with ascites. ( Fuller, R; Hoppel, C; Ingalls, ST, 1981) |
| "Mobilization of ascites was studied in 20 anesthetized dogs with experimental cirrhosis following a mannitol- or furosemide-induced diuresis." | 7.66 | Mobilization of ascites in cirrhotic dogs following furosemide or mannitol diuresis. ( Levy, M; Richard, C, 1978) |
| " To develop an effective but safe regimen for treatment of cirrhotic ascites, a two-part crossover study was done." | 6.64 | An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide. ( Fuller, RK; Gobezie, GC; Khambatta, PB, 1977) |
| "Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV." | 5.46 | Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017) |
| "Combined use of furosemide with albumin is an approved therapy to overcome diuretic resistance in treatment of ascites in decompensated chronic liver disease." | 5.34 | Comparative Study of Slow Infusion versus Bolus Doses of Albumin and Furosemide Infusion to Mobilize Refractory Ascites in Decompensated Chronic Liver Disease. ( Jha, A; Kafle, B; Khadga, P; Pathak, R; Thapaliya, S; Yadav, AK, 2020) |
| "This study aimed to assess the influence to the renal function by furosemide dose reductions after administration of tolvaptan in cirrhotic ascites patients." | 5.34 | Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. ( Hidaka, H; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shibuya, A; Sung, JH; Tanaka, Y; Uojima, H; Wada, N, 2020) |
| " Identification of patients who will not respond to diuretic therapy usually requires several weeks of observation during which a trial of diuretics is instituted using stepwise increases in dosage in order to classify ascites as refractory." | 5.31 | Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. ( Pomier-Layrargues, G; Spahr, L; Tran, HK; Villeneuve, JP, 2001) |
| "Furosemide treatment was performed in 26 HC patients." | 5.28 | [Effect of furosemide on the renal prostaglandin system in liver cirrhosis with ascites]. ( Dustov, AD; Mansurov, KhKh, 1989) |
| " We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months." | 5.27 | Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. ( Airoldi, A; Alessandria, C; Andrealli, A; Angeli, P; Angelico, M; Baldassarre, M; Ballardini, G; Bernardi, M; Boccia, S; Cacciola, I; Cappa, FM; Caraceni, P; Cavallin, M; Cesarini, L; Cozzolongo, R; De Marco, R; Di Marco, V; Elia, C; Elia, G; Fagiuoli, S; Federico, A; Fidone, F; Foschi, FG; Galioto, A; Guarisco, R; Levantesi, F; Massironi, S; Morisco, F; Nardelli, S; Neri, S; Pasquale, C; Piano, S; Prestianni, L; Rendina, M; Riggio, O; Romanelli, RG; Roncadori, A; Ruggeri, M; Sangiovanni, V; Simone, L; Svegliati-Baroni, G; Toniutto, P; Tortora, A; Tufoni, M; Zaccherini, G, 2018) |
| " In the present study a plethysmographic technique was utilized to record the rate of absorption of fluid from the peritoneal cavity of anesthetized cats." | 5.26 | Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis. ( Greenway, CV; Zink, J, 1977) |
| " Patients without hyperkalemia were administrated 100 mg of spironolactone/day." | 5.22 | High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. ( Demir, M; Dogan, O; Ozer, B; Parlakgumus, A; Serin, E; Yakar, T, 2016) |
| "To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites." | 5.14 | Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. ( Cammà, C; Craxì, A; Di Raimondo, D; Di Sciacca, R; Licata, A; Licata, G; Parrinello, G; Paterna, S; Pinto, A; Tuttolomondo, A, 2009) |
| "Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was -0." | 5.14 | Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. ( Bruha, R; Dudley, F; Ginès, P; Terg, R; Watson, H; Wong, F; Zarski, JP, 2010) |
| "Tolvaptan was orally administrated at titrated doses of 15, 30, and 60 mg once daily after breakfast for 3 days at each dose to 18 liver cirrhosis patients with persistent ascites and/or lower limb edema despite receiving oral furosemide at 40 mg/day or higher." | 5.14 | A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. ( Chayama, K; Kaneko, A; Kato, M; Murawaki, Y; Okada, M; Okita, K; Ono, N; Sakaida, I; Sata, M; Yoshihara, H; Yoshihara, N, 2010) |
| "To conduct a randomized, double-blind, placebo-controlled, cross-over study to test the hypothesis that midodrine significantly increases natriuretic response of IV furosemide in non-azotemic cirrhotics with ascites." | 5.14 | The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. ( Chalasani, N; Hamman, M; Jones, D; Kahi, C; Kwo, PY; Misra, VL; Vuppalanchi, R, 2010) |
| "Twenty nonazotemic cirrhotic patients with ascites were treated with furosemide and spironolactone." | 5.12 | The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites. ( Economou, M; Kalambokis, G; Kosta, P; Papadimitriou, K; Tsianos, EV, 2006) |
| "To investigate the safety and tolerability of RWJ-351647 compared with placebo after single oral dose administration to patients with cirrhosis and ascites, on a stable treatment with furosemide and spironolactone." | 5.12 | Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ( Korula, J; Maheshwari, A; Parikh, C; Schrier, RW; Steare, S; Thuluvath, PJ; Wong, F; Yoo, HW, 2006) |
| "The effects of the addition of clonidine to diuretics on the mobilization of ascites in the short term (diuretic response and requirement of diuretics) and the long term (readmissions for tense ascites and requirement of diuretics) were examined in patients with cirrhosis and with increased sympathetic nervous system (SNS) activity." | 5.12 | Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. ( Codden, T; Henry, JP; Lenaerts, A; Ligny, G; Meunier, JC, 2006) |
| " This investigation consists of a double-blind, randomized, placebo-controlled trial aimed at comparing the effects of the selective COX-2 inhibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites." | 5.11 | Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. ( Arroyo, V; Clària, J; Escolar, G; Ginès, P; Jiménez, W; Kent, JD; López-Parra, M; Ruiz-Del-Arbol, L; Vucelic, B, 2005) |
| "The most rational treatment of moderate ascites is spironolactone alone or in combination with furosemide." | 5.10 | Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. ( Cabré, E; Durández, R; Gassull, MA; Granada, ML; Jiménez, JA; Morillas, RM; Pardo, A; Planas, R; Quintero, E; Santos, J, 2003) |
| "These results show that torsemide is as effective and safe as frusemide for long-term treatment of cirrhotic patients with ascites." | 5.09 | Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites. ( Abecasis, R; Cobas, S; Guevara, M; Miguez, C; Terg, R, 2001) |
| "To evaluate the pharmacokinetics and pharmacodynamics of furosemide and torasemide in patients with cirrhosis and diuretic resistant ascites." | 5.08 | Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites. ( Bernareggi, A; Buzzelli, G; Carloni, V; Chibbaro, G; Cotrozzi, G; Foschi, M; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Melani, L; Quartini, M; Simoni, A; Tommasi, AC, 1996) |
| "Twenty patients with cirrhosis and ascites were randomly divided in two groups to receive 20 mg/die of the new-loop-diuretic torasemide (T), and 50 mg/die of furosemide (F)." | 5.08 | [Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients]. ( Bodini, P; Dizioli, P; Marelli, A; Quinzani, M; Reggiani, A; Tonghini, L, 1997) |
| "In a prospective randomized short-term study, the efficacy and safety of xipamide and a combination of spironolactone and furosemide were compared in the treatment of hepatic cirrhotic ascites." | 5.07 | Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide. ( Knauf, H; Mutschler, E, 1994) |
| " Both drugs were administered in association with spironolactone (200 mg/day) in 28 nonazotemic cirrhotic patients with controlled ascites." | 5.07 | Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study. ( Elia, G; Fiaccadori, F; Pasetti, G; Pedretti, G; Pizzaferri, P, 1993) |
| "The effects of torasemide (20 mg/day) and furosemide (50 mg/day), each given over 4 days, were compared in a randomized and crossover study carried out in seven patients with cirrhosis and tense ascites." | 5.07 | Torasemide in the treatment of patients with cirrhosis and ascites. ( Carloni, V; Foschi, M; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Romanelli, RG, 1993) |
| "Forty patients with cirrhosis of the liver and tense ascites were randomized to receive either aldactone 400 mg/day and furosemide 80 mg/day (n = 20) or repeated large volume paracentesis (LVP) and infusion of low molecular weight dextran (n = 20)." | 5.07 | Large volume paracentesis and intravenous dextran to treat tense ascites. ( Acharya, SK; Balwinder, S; Nijhawan, S; Padhee, AK; Tandon, BN, 1992) |
| "In a randomized double-blind trial we compared the effects of torasemide, a new loop diuretic, and furosemide in nonazotemic cirrhotic patients with ascites during a 3-day period in association with potassium canrenoate (200 mg/day) administration." | 5.07 | Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study. ( Azzena, G; Buzzelli, G; De Feo, ML; Gentilini, P; La Villa, G; Laffi, G; Marra, F; Meacci, E, 1991) |
| "In a randomized prospective study the efficacy and side effects of xipamide versus the combination spironolactone/furosemide in the treatment of cirrhotic ascites were studied." | 5.06 | Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion. ( Gerok, W; Goerg, KJ; Knauf, H; Leser, HG; Mutschler, E; Schölmerich, J; Wenk, E, 1990) |
| "To compare the efficacy of three commonly used diuretic regimens in the treatment of ascites, we randomized 90 patients to three treatment groups: Sequential Spironolactone (spironolactone followed by furosemide if necessary), Combination (spironolactone and furosemide in combination), and Furosemide (furosemide given alone)." | 5.05 | Diuresis in the ascitic patient: a randomized controlled trial of three regimens. ( Fogel, MR; Gregory, PB; Knauer, CM; Miller, RG; Neal, EA; Sawhney, VK, 1981) |
| "Nonsteroidal anti-inflammatory drugs (NSAID) suppress prostaglandin-dependent renal blood flow and furosemide-induced diuresis in patients with cirrhosis and ascites." | 5.05 | Sulindac and indomethacin suppress the diuretic action of furosemide in patients with cirrhosis and ascites: evidence that sulindac affects renal prostaglandins. ( Daskalopoulos, G; Gonzalez, M; Katkov, W; Kronborg, I; Laffi, G; Zipser, RD, 1985) |
| " Our group has shown that treatment of patients with diuretic-resistant heart failure with high-dose furosemide plus hypertonic saline is effective and well tolerated, improving symptoms of congestion, reducing plasma levels of markers of neurohormonal and inflammatory activation, decreasing hospital readmission rates, and reducing long-term mortality." | 4.87 | Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites. ( Licata, G; Parrinello, G; Pinto, A; Tuttolomondo, A, 2011) |
| "To evaluate the clinical usefulness of combined furosemide and human albumin for the treatment of diuretic-resistant edema in patients with nephrotic syndrome and cirrhosis." | 4.82 | Combined furosemide and human albumin treatment for diuretic-resistant edema. ( Eisele, G; Elwell, RJ; Spencer, AP, 2003) |
| "Ninety cirrhotic patients with ascites were studied after administration of HSS infusion (n=25) or etilefrine tablets (n=25), or both (n=25) plus standard diuretics therapy (SDT), or SDT alone (n=15)." | 4.12 | Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites. ( Badra, G; El-Haggar, S; El-Said, H; Ibrahim, O; Radwan, H, 2022) |
| "This study investigated time-course changes in skeletal muscle volume per year with tolvaptan in patients with refractory ascites that was unresponsive to loop diuretics and aldosterone antagonists." | 3.96 | Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. ( Aikata, H; Chayama, K; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kodama, K; Morio, K; Murakami, E; Nakahara, T; Namba, M; Ohya, K; Tsuge, M; Uchikawa, S; Yamauchi, M, 2020) |
| "Therapeutic response to tolvaptan was associated with longer survival in cirrhosis patients complicated with ascites." | 3.91 | Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites. ( Kida, Y, 2019) |
| "In human cirrhosis, adrenergic hyperfunction causes proximal tubular fluid retention and contributes to diuretic-resistant ascites, and clonidine, a sympatholytic drug, improves natriuresis in difficult-to-treat ascites." | 3.83 | Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine. ( Aragno, M; Mastrocola, R; Mengozzi, G; Parola, M; Sansoè, G, 2016) |
| "We evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites." | 3.83 | Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites. ( Bellia, C; Ciaccio, M; Clemente, G; Di Bona, D; Di Raimondo, D; Gulotta, E; Maida, C; Pecoraro, R; Pinto, A; Simonetta, I; Tuttolomondo, A; Vassallo, V, 2016) |
| "Tolvaptan is a new drug used for treating ascites induced by liver cirrhosis, and it is covered by health insurance in Japan." | 3.81 | Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites. ( Goto, A; Matsumoto, M; Nakamura, M; Sakaida, I; Terai, S, 2015) |
| "To present an atypical case of massive ascites and hydrothorax after leuprolide acetate administration in a down-regulated woman undergoing assisted reproduction." | 3.74 | Massive ascites and hydrothorax after leuprolide acetate administration in a down-regulated woman undergoing assisted reproduction. ( Coppola, F; Ferrari, B; Pezzuto, A, 2007) |
| "The unique pattern of cardiac ascites should allow for rapid diagnosis and characterization: The clinical implications of furosemide use in its response and biochemical properties warrant further description." | 3.74 | Characteristics of ascitic fluid in cardiac ascites. ( Christou, L; Economou, G; Economou, M; Kolettis, TM; Tsianos, EV, 2007) |
| "To verify prospectively the usefulness of the furosemide-induced natriuresis test in predicting ascites control by medical treatment, 15 stable cirrhotics (9 male) with ascites were studied." | 3.73 | The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusion. ( Apollonio, L; Bartoli, EG; Fabris, C; Pirisi, M; Sereti, K; Toniutto, P, 2006) |
| "In out-patient departments, the measurement of urine sodium 8 hours after administrating 80 mg of intravenous furosemide, will help in differentiating ascites patients with lower treatment response to diuretics." | 3.72 | [The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis]. ( Cho, HS; Choi, HS; Hahm, JS; Kim, JB; Kim, YH; Lee, MH; Lee, OY; Park, GT; Shim, SG, 2003) |
| "Twenty-seven patients with nonazotemic liver cirrhosis and ascites were initially treated with spironolactone, 200 mg/day." | 3.70 | Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients. ( Banić, M; Kujundzić, M; Ljubicić, N; Vrkljan, M, 1998) |
| " Recombinant human serum albumin (rHSA) (1 g/kg) significantly decreased the weight of ascites in rats with puromycin aminonucleoside-induced nephropathy." | 3.70 | Effects of recombinant human serum albumin on ascites in rats with puromycin aminonucleoside-induced nephropathy. ( Hanada, S; Maruyama, T; Matsui, T; Nakamura, N; Shintome, M; Tsuchiyama, H; Tsukada, M; Yuki, T, 1998) |
| "We investigated the effects of KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine), a potent adenosine A1-receptor antagonist, on the nephrotic edema induced by puromycin aminonucleoside (PAN; 100 mg/kg, i." | 3.69 | Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats. ( Karasawa, A; Kusaka, H; Nagashima, K, 1995) |
| "We describe the successful use of combined ascitic-fluid and furosemide infusion as a therapeutic option in the management of massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis in a 30-year-old Nigerian male farmer." | 3.68 | Combined ascitic--fluid and furosemide infusion: a therapeutic option for massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis. ( Ijoma, CK; Nusiem, CA; Nwaneri, O; Offodile, AA; Onuigbo, MA; Onyeagocha, AC; Ozoh, JO, 1991) |
| "Plasma concentrations of atrial natriuretic factor (ANF) and cyclic 3',5'-guanosine monophosphate (cGMP) were measured in 11 cirrhotic patients with ascites, 11 cirrhotic patients without ascites and 15 control subjects." | 3.68 | Atrial natriuretic factor, cyclic 3',5'-guanosine monophosphate and prostaglandin E2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide. ( Jensen, L; Jespersen, B; Pedersen, EB; Sørensen, SS, 1990) |
| "Propranolol hydrochloride is reported to lower portal pressure and inhibit renin secretion in patients with chronic liver disease, actions that might lessen the tendency to ascites formation." | 3.67 | Propranolol in the treatment of cirrhotic ascites. ( Rector, WG; Reynolds, TB, 1984) |
| "In cirrhotic patients low-dose captopril seems to be efficient in the treatment of ascites resistant to diuretics without causing major side effects." | 3.67 | [Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites]. ( Brunkhorst, R; Koch, K; Kühn, K; Schmidt, FW; Wrenger, E, 1989) |
| "Furosemide occasionally causes azotemia in patients with ascites, independently of induced volume depletion." | 3.67 | Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites. ( Daskalopoulos, G; Harley, H; Laffi, G; Morgan, T; Pinzani, M; Reynolds, T; Zipser, RD, 1987) |
| "We have studied the efficacy of urea in the treatment of hyponatremia and hydrosaline retention in cirrhotic patients with ascites resistant to diuretics." | 3.67 | Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. ( Cauchie, P; Decaux, G; Delwiche, F; Flamion, B; Mols, P, 1986) |
| "The pharmacokinetics of furosemide was studied in 7 patients with diagnosed liver cirrhosis and in 7 healthy subjects." | 3.66 | Pharmacokinetics of furosemide in patients with hepatic cirrhosis. ( Antezana, C; Arancibia, A; Caro, P; González, G; Rivas, MI, 1982) |
| "Furosemide, 20 mg, was given intravenously as a bolus to seven patients with cirrhotic ascites and a 10-mg intravenous bolus dose was given to three normal subjects." | 3.66 | Furosemide kinetics in patients with hepatic cirrhosis with ascites. ( Fuller, R; Hoppel, C; Ingalls, ST, 1981) |
| "Five patients with hepatorenal syndrome were treated with a LeVeen peritoneovenous shunt and furosemide." | 3.66 | Treatment of hepatorenal syndrome. ( Schwartz, ML; Vogel, SB, 1980) |
| "Mobilization of ascites was studied in 20 anesthetized dogs with experimental cirrhosis following a mannitol- or furosemide-induced diuresis." | 3.66 | Mobilization of ascites in cirrhotic dogs following furosemide or mannitol diuresis. ( Levy, M; Richard, C, 1978) |
| "Fifty patients with Child-Pugh C liver cirrhosis and tense ascites were randomly allocated into 5 groups." | 2.71 | Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial. ( Degoricija, V; Marout, J; Sefer, S; Troskot, B; Zjacic-Rotkvic, V, 2003) |
| "In order to clarify debated issues of the medical treatment of ascites in cirrhosis--the usefulness of a low sodium diet and washout period preceding diuretic administration, maximal dosage of antimineralocorticoid to be reached before the addition of a loop diuretic, identifications of factors influencing treatment efficacy--115 hospitalized patients with non-azotemic cirrhosis and ascites were recruited and randomized to receive a diet providing either 40 or 120 mmol of sodium daily." | 2.67 | Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content. ( Azzena, G; Bernardi, M; Bonato, S; Gasbarrini, G; Gentilini, P; Laffi, G; Marra, F; Naccarato, R; Salvagnini, M; Trevisani, F, 1993) |
| " To develop an effective but safe regimen for treatment of cirrhotic ascites, a two-part crossover study was done." | 2.64 | An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide. ( Fuller, RK; Gobezie, GC; Khambatta, PB, 1977) |
| "Bumetanide and frusemide were compared in a crossover study of 10 patients with cirrhosis and fluid overload." | 2.64 | Treatment of fluid retention in cirrhosis: a comparison of bumetanide and frusemide. ( Nicholson, G, 1977) |
| "Spironolactone has long been a standard for the treatment of cirrhotic ascites because it directly antagonizes aldosterone." | 2.38 | Medical treatment of ascites in cirrhosis. ( Gerbes, AL, 1993) |
| "In dapagliflozin-treated NASH mice, hypoglycemia was not identified during 24-hour casual blood glucose monitoring." | 1.56 | Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes. ( Nakamoto, K; Tsubakimoto, M; Yabiku, K, 2020) |
| "Sarcoidosis is a multisystem granulomatous inflammatory disorder frequently affecting the lungs, but also the liver, along with cirrhosis and portal hypertension occurring in less than 1% of the patients." | 1.51 | Finger clubbing and cirrhosis in a sarcoidosis patient. ( Bilir, M; Tetikkurt, C; Yanardag, H, 2019) |
| "Coexistent hepatocellular carcinoma (HCC) was the only significant predictive variable that attenuated the efficacy of TLV." | 1.46 | Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. ( Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M, 2017) |
| "A diagnosis of dilated cardiomyopathy with cardiorenal syndrome was made, most likely secondary to viral myocarditis in view of his initial presentation." | 1.42 | The failing heart: a bad case of the 'flu'. ( Akhtar, MM; Emmanuel, J; Modi, B; Wilson, J, 2015) |
| "Ascites, variceal bleeding, hepatic encephalopathy, and hepatorenal syndrome are among the complications you are likely to encounter when caring for a patient with cirrhosis." | 1.42 | Cirrhosis complications: keeping them under control. ( Eliacin, I; Kashan, S; Minor, SE; Whisenant, EB, 2015) |
| "Budd-Chiari and celiac sprue association is a rare condition." | 1.32 | Budd-Chiari syndrome in a young patient with celiac sprue: a case report. ( Beşişik, F; Cakaloğlu, Y; Cevikbaş, U; Danalioğlu, A; Demir, K; Güngör Güllüoğlu, M; Okten, A; Poturoğlu, S, 2003) |
| " Identification of patients who will not respond to diuretic therapy usually requires several weeks of observation during which a trial of diuretics is instituted using stepwise increases in dosage in order to classify ascites as refractory." | 1.31 | Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. ( Pomier-Layrargues, G; Spahr, L; Tran, HK; Villeneuve, JP, 2001) |
| "Ascites in liver cirrhosis is a symptom of advanced liver disease, and liver transplantation should always be considered in eligible patients." | 1.31 | [Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy]. ( Lööf, L; Prytz, H; Söderlund, C; Wallerstedt, S, 2001) |
| "Furosemide treatment was performed in 26 HC patients." | 1.28 | [Effect of furosemide on the renal prostaglandin system in liver cirrhosis with ascites]. ( Dustov, AD; Mansurov, KhKh, 1989) |
| "In three patients, pulmonary edema did not occur; in one patient, pulmonary edema occurred transiently but responded to furosemide administration." | 1.26 | Hemodynamics of LeVeen shunt pulmonary edema. ( Ansley, JD; Darsee, JR; Fulenwider, JT; Heymsfield, SB; Ivey, G; Nordlinger, BF; Rikkers, LF, 1981) |
| " Furosemide bioavailability was the same in cirrhotic subjects and controls." | 1.26 | Furosemide disposition in cirrhotic patients. ( Blaschke, TF; Gregory, PB; Sawhney, VK; Swezey, SE, 1981) |
| "Forty patients with generalized cancer complicated by water and electrolyte retention were treated with "medium" and "large" doses of furosemide and bumetanide with 35% and 40% objective positive response, respectively." | 1.26 | Diuretics in malignant effusions and edemas of generalized cancer. ( Athanasiou, A; Dadiotis, L; Razis, DV, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 108 (56.25) | 18.7374 |
| 1990's | 27 (14.06) | 18.2507 |
| 2000's | 25 (13.02) | 29.6817 |
| 2010's | 27 (14.06) | 24.3611 |
| 2020's | 5 (2.60) | 2.80 |
| Authors | Studies |
|---|---|
| Radwan, H | 1 |
| Ibrahim, O | 1 |
| Badra, G | 1 |
| El-Said, H | 1 |
| El-Haggar, S | 1 |
| Namba, M | 1 |
| Hiramatsu, A | 1 |
| Aikata, H | 1 |
| Kodama, K | 1 |
| Uchikawa, S | 1 |
| Ohya, K | 1 |
| Morio, K | 1 |
| Fujino, H | 1 |
| Nakahara, T | 1 |
| Murakami, E | 1 |
| Yamauchi, M | 1 |
| Kawaoka, T | 1 |
| Tsuge, M | 1 |
| Imamura, M | 1 |
| Chayama, K | 2 |
| Yanardag, H | 1 |
| Tetikkurt, C | 1 |
| Bilir, M | 1 |
| Pathak, R | 1 |
| Yadav, AK | 1 |
| Thapaliya, S | 1 |
| Kafle, B | 1 |
| Jha, A | 1 |
| Khadga, P | 1 |
| Yabiku, K | 1 |
| Nakamoto, K | 1 |
| Tsubakimoto, M | 1 |
| Miyazaki, M | 1 |
| Yada, M | 1 |
| Tanaka, K | 1 |
| Senjyu, T | 1 |
| Goya, T | 1 |
| Motomura, K | 1 |
| Kohjima, M | 1 |
| Kato, M | 3 |
| Masumoto, A | 1 |
| Kotoh, K | 1 |
| Uojima, H | 2 |
| Hidaka, H | 3 |
| Nakayama, T | 1 |
| Sung, JH | 2 |
| Ichita, C | 1 |
| Tokoro, S | 1 |
| Masuda, S | 1 |
| Sasaki, A | 1 |
| Koizumi, K | 1 |
| Egashira, H | 1 |
| Kako, M | 2 |
| Caraceni, P | 1 |
| Riggio, O | 1 |
| Angeli, P | 2 |
| Alessandria, C | 1 |
| Neri, S | 1 |
| Foschi, FG | 1 |
| Levantesi, F | 1 |
| Airoldi, A | 1 |
| Boccia, S | 1 |
| Svegliati-Baroni, G | 1 |
| Fagiuoli, S | 1 |
| Romanelli, RG | 3 |
| Cozzolongo, R | 1 |
| Di Marco, V | 1 |
| Sangiovanni, V | 1 |
| Morisco, F | 1 |
| Toniutto, P | 2 |
| Tortora, A | 1 |
| De Marco, R | 1 |
| Angelico, M | 1 |
| Cacciola, I | 1 |
| Elia, G | 2 |
| Federico, A | 1 |
| Massironi, S | 1 |
| Guarisco, R | 1 |
| Galioto, A | 2 |
| Ballardini, G | 1 |
| Rendina, M | 1 |
| Nardelli, S | 1 |
| Piano, S | 1 |
| Elia, C | 1 |
| Prestianni, L | 1 |
| Cappa, FM | 1 |
| Cesarini, L | 1 |
| Simone, L | 1 |
| Pasquale, C | 1 |
| Cavallin, M | 1 |
| Andrealli, A | 1 |
| Fidone, F | 1 |
| Ruggeri, M | 1 |
| Roncadori, A | 1 |
| Baldassarre, M | 1 |
| Tufoni, M | 1 |
| Zaccherini, G | 1 |
| Bernardi, M | 2 |
| Kida, Y | 1 |
| Tanaka, Y | 1 |
| Wada, N | 1 |
| Kubota, K | 1 |
| Nakazawa, T | 1 |
| Shibuya, A | 1 |
| Koizumi, W | 1 |
| Iwasa, M | 1 |
| Ishihara, T | 1 |
| Isoai, A | 1 |
| Kobayashi, R | 1 |
| Torii, N | 1 |
| Soneda, N | 1 |
| Takei, Y | 1 |
| Zhu, YF | 1 |
| Gu, XB | 1 |
| Zhu, HY | 1 |
| Yang, XJ | 1 |
| Wang, D | 1 |
| Yu, P | 1 |
| Perri, GA | 1 |
| Goto, A | 1 |
| Terai, S | 1 |
| Nakamura, M | 1 |
| Matsumoto, M | 1 |
| Sakaida, I | 2 |
| Wilson, J | 1 |
| Akhtar, MM | 1 |
| Modi, B | 1 |
| Emmanuel, J | 1 |
| Storm, J | 1 |
| Taylor, M | 1 |
| Mitchell, M | 1 |
| Loughrey, M | 1 |
| Mainie, I | 1 |
| Minor, SE | 1 |
| Eliacin, I | 1 |
| Kashan, S | 1 |
| Whisenant, EB | 1 |
| Gamblin, V | 1 |
| Da Silva, A | 1 |
| Villet, S | 1 |
| El Hajbi, F | 1 |
| Sansoè, G | 2 |
| Aragno, M | 2 |
| Mastrocola, R | 2 |
| Parola, M | 2 |
| Mengozzi, G | 1 |
| Yakar, T | 1 |
| Demir, M | 1 |
| Dogan, O | 1 |
| Parlakgumus, A | 1 |
| Ozer, B | 1 |
| Serin, E | 1 |
| Tuttolomondo, A | 3 |
| Di Raimondo, D | 2 |
| Bellia, C | 1 |
| Clemente, G | 1 |
| Pecoraro, R | 1 |
| Maida, C | 1 |
| Simonetta, I | 1 |
| Vassallo, V | 1 |
| Di Bona, D | 1 |
| Gulotta, E | 1 |
| Ciaccio, M | 1 |
| Pinto, A | 3 |
| Licata, G | 2 |
| Licata, A | 1 |
| Parrinello, G | 2 |
| Di Sciacca, R | 1 |
| Cammà, C | 1 |
| Craxì, A | 1 |
| Paterna, S | 1 |
| Fasolato, S | 1 |
| Mazza, E | 1 |
| Okolicsanyi, L | 1 |
| Maresio, G | 1 |
| Velo, E | 1 |
| Salinas, F | 1 |
| D'Aquino, M | 1 |
| Sticca, A | 1 |
| Gatta, A | 1 |
| Hou, W | 1 |
| Sanyal, AJ | 1 |
| Ginès, P | 6 |
| Wong, F | 3 |
| Watson, H | 1 |
| Terg, R | 2 |
| Bruha, R | 1 |
| Zarski, JP | 1 |
| Dudley, F | 1 |
| Okita, K | 1 |
| Okada, M | 1 |
| Kaneko, A | 1 |
| Sata, M | 1 |
| Yoshihara, H | 1 |
| Yoshihara, N | 1 |
| Ono, N | 1 |
| Murawaki, Y | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Touloumis, L | 1 |
| Chatzopoulos, D | 1 |
| Kalambokis, G | 3 |
| Tsianos, EV | 4 |
| Misra, VL | 1 |
| Vuppalanchi, R | 1 |
| Jones, D | 1 |
| Hamman, M | 1 |
| Kwo, PY | 1 |
| Kahi, C | 1 |
| Chalasani, N | 3 |
| Rogers, NA | 1 |
| Gupta, S | 1 |
| Cuthbert, JA | 1 |
| Degoricija, V | 1 |
| Zjacic-Rotkvic, V | 1 |
| Marout, J | 1 |
| Sefer, S | 1 |
| Troskot, B | 1 |
| Elwell, RJ | 1 |
| Spencer, AP | 1 |
| Eisele, G | 1 |
| Santos, J | 1 |
| Planas, R | 4 |
| Pardo, A | 1 |
| Durández, R | 1 |
| Cabré, E | 1 |
| Morillas, RM | 1 |
| Granada, ML | 1 |
| Jiménez, JA | 1 |
| Quintero, E | 3 |
| Gassull, MA | 1 |
| EL-BADRY, R | 1 |
| KHALIFA, K | 1 |
| EL-AYADI, A | 1 |
| EL-SAFORI, S | 1 |
| TOPUZADA, S | 2 |
| LEONDEFF, J | 1 |
| MASTRANGELO, F | 1 |
| D AGOSTINO, F | 1 |
| PASTORE, G | 1 |
| BARACCHI, G | 1 |
| CAPPAI, G | 1 |
| GIACOMASSO, P | 1 |
| TOMAT, E | 2 |
| Boughattas, S | 1 |
| Hassine, H | 1 |
| Chatti, K | 1 |
| Salem, N | 1 |
| Essabbah, H | 1 |
| Cho, HS | 1 |
| Park, GT | 1 |
| Kim, YH | 1 |
| Shim, SG | 1 |
| Kim, JB | 1 |
| Lee, OY | 1 |
| Choi, HS | 1 |
| Hahm, JS | 1 |
| Lee, MH | 1 |
| Danalioğlu, A | 1 |
| Poturoğlu, S | 1 |
| Güngör Güllüoğlu, M | 1 |
| Demir, K | 1 |
| Beşişik, F | 1 |
| Cakaloğlu, Y | 1 |
| Cevikbaş, U | 1 |
| Okten, A | 1 |
| Goenaga, MA | 1 |
| Millet, M | 1 |
| Sánchez, E | 1 |
| Garde, C | 1 |
| Carrera, JA | 1 |
| Arzellus, E | 1 |
| Clària, J | 2 |
| Kent, JD | 1 |
| López-Parra, M | 2 |
| Escolar, G | 1 |
| Ruiz-Del-Arbol, L | 1 |
| Jiménez, W | 3 |
| Vucelic, B | 1 |
| Arroyo, V | 6 |
| Di Costanzo, GG | 1 |
| Ragozzino, A | 1 |
| Niola, R | 1 |
| Maglione, F | 1 |
| Ascione, A | 1 |
| Economou, M | 2 |
| Kosta, P | 1 |
| Papadimitriou, K | 1 |
| Thuluvath, PJ | 1 |
| Maheshwari, A | 1 |
| Yoo, HW | 1 |
| Schrier, RW | 1 |
| Parikh, C | 1 |
| Steare, S | 1 |
| Korula, J | 1 |
| Lenaerts, A | 2 |
| Codden, T | 2 |
| Meunier, JC | 2 |
| Henry, JP | 2 |
| Ligny, G | 2 |
| Pirisi, M | 1 |
| Fabris, C | 1 |
| Apollonio, L | 1 |
| Sereti, K | 1 |
| Bartoli, EG | 1 |
| Ferrari, B | 1 |
| Pezzuto, A | 1 |
| Coppola, F | 1 |
| Christou, L | 1 |
| Economou, G | 1 |
| Kolettis, TM | 1 |
| Mehta, RL | 1 |
| Cantarovich, F | 1 |
| Shaw, A | 1 |
| Hoste, E | 1 |
| Murray, P | 1 |
| Earley, LE | 1 |
| Shafei, AZ | 1 |
| Habib, YA | 1 |
| el-Khangry, HA | 1 |
| Abou-Khair, SA | 1 |
| Abaza, HH | 1 |
| Nibal, AH | 1 |
| Zwierzina, WD | 1 |
| Kunz, F | 1 |
| Judmaier, G | 1 |
| Mikuz, G | 1 |
| Gattringer, K | 1 |
| Migneco, G | 1 |
| Mascarella, A | 1 |
| Tripi, S | 1 |
| La Cascia, C | 1 |
| Di Caro, R | 1 |
| Pérez-Ayuso, RM | 1 |
| Gaya, J | 1 |
| Bory, F | 3 |
| Rimola, A | 3 |
| Rivera, F | 2 |
| Rodés, J | 3 |
| Descos, L | 1 |
| Gauthier, A | 1 |
| Levy, VG | 1 |
| Michel, H | 1 |
| Quinton, A | 1 |
| Rueff, B | 1 |
| Fermanian, J | 1 |
| Fombonne, E | 1 |
| Durbec, JP | 1 |
| Lissen Otero, E | 1 |
| Leal Noval, M | 1 |
| Lozano de León-Naranjo, F | 1 |
| Sánchez Quijano, A | 1 |
| Peláez Domínguez, S | 1 |
| Miranda Guisado, ML | 1 |
| Relimpio Ferrer, F | 1 |
| Andreu Kern, F | 1 |
| Amiel, SA | 1 |
| Blackburn, AM | 1 |
| Rubens, RD | 1 |
| Rector, WG | 3 |
| Reynolds, TB | 3 |
| Schumpelick, V | 1 |
| Hrynyschyn, K | 1 |
| Kortmann, KB | 1 |
| Boyer, TD | 1 |
| Warnock, DG | 1 |
| Fogel, MR | 1 |
| Sawhney, VK | 2 |
| Neal, EA | 1 |
| Miller, RG | 1 |
| Knauer, CM | 1 |
| Gregory, PB | 2 |
| González, G | 1 |
| Arancibia, A | 1 |
| Rivas, MI | 1 |
| Caro, P | 1 |
| Antezana, C | 1 |
| Capussotti, L | 1 |
| Aricò, S | 1 |
| Marucci, M | 1 |
| Dellepiane, M | 1 |
| De La Pierre, M | 1 |
| Henriksen, JH | 1 |
| Parving, HH | 1 |
| Lassen, NA | 1 |
| Winkler, K | 1 |
| Pupita, F | 2 |
| Ansuini, R | 2 |
| Frausini, G | 1 |
| Darsee, JR | 1 |
| Fulenwider, JT | 1 |
| Rikkers, LF | 1 |
| Ansley, JD | 1 |
| Nordlinger, BF | 1 |
| Ivey, G | 1 |
| Heymsfield, SB | 1 |
| Furrer, J | 2 |
| Hess, OM | 1 |
| Kuhlmann, U | 1 |
| Satz, N | 1 |
| Siegenthaler, W | 2 |
| Fuller, R | 1 |
| Hoppel, C | 1 |
| Ingalls, ST | 1 |
| Swezey, SE | 1 |
| Blaschke, TF | 1 |
| Schwartz, ML | 1 |
| Vogel, SB | 1 |
| Clearfield, H | 1 |
| Gentilini, P | 6 |
| Milani, A | 2 |
| Ciammella, AM | 2 |
| Rossi, L | 2 |
| Kusaka, H | 1 |
| Nagashima, K | 1 |
| Karasawa, A | 1 |
| Van Vliet, AA | 1 |
| Kröger, R | 1 |
| Dubbelman, R | 1 |
| Ten Bokkel-Huinink, WW | 1 |
| Knauf, H | 3 |
| Mutschler, E | 3 |
| Salerno, F | 1 |
| Lorenzano, E | 1 |
| Maggi, A | 1 |
| Badalamenti, S | 2 |
| Minuz, P | 1 |
| Degan, M | 1 |
| Chinea, B | 1 |
| Scotti, A | 1 |
| Gerbes, AL | 2 |
| Bertheau-Reitha, U | 1 |
| Falkner, C | 1 |
| Jüngst, D | 1 |
| Paumgartner, G | 1 |
| Laffi, G | 7 |
| Salvagnini, M | 1 |
| Azzena, G | 2 |
| Bonato, S | 1 |
| Marra, F | 4 |
| Trevisani, F | 1 |
| Gasbarrini, G | 1 |
| Naccarato, R | 2 |
| Fiaccadori, F | 1 |
| Pedretti, G | 1 |
| Pasetti, G | 1 |
| Pizzaferri, P | 1 |
| La Villa, G | 4 |
| Carloni, V | 2 |
| Foschi, M | 2 |
| Melani, L | 1 |
| Cotrozzi, G | 1 |
| Quartini, M | 1 |
| Chibbaro, G | 1 |
| Tommasi, AC | 1 |
| Bernareggi, A | 1 |
| Simoni, A | 1 |
| Buzzelli, G | 3 |
| Chang, SC | 1 |
| Chang, HI | 1 |
| Chen, FJ | 1 |
| Shiao, GM | 1 |
| Wang, SS | 1 |
| Lee, SD | 1 |
| Marelli, A | 1 |
| Bodini, P | 1 |
| Reggiani, A | 1 |
| Quinzani, M | 1 |
| Dizioli, P | 1 |
| Tonghini, L | 1 |
| Ljubicić, N | 1 |
| Kujundzić, M | 1 |
| Banić, M | 1 |
| Vrkljan, M | 1 |
| Tsukada, M | 1 |
| Shintome, M | 1 |
| Matsui, T | 1 |
| Tsuchiyama, H | 1 |
| Maruyama, T | 1 |
| Yuki, T | 1 |
| Hanada, S | 1 |
| Nakamura, N | 1 |
| Casini-Raggi, V | 1 |
| Di Fiore, G | 1 |
| Pinzani, M | 2 |
| Blendis, L | 1 |
| Spahr, L | 1 |
| Villeneuve, JP | 2 |
| Tran, HK | 1 |
| Pomier-Layrargues, G | 1 |
| Abecasis, R | 1 |
| Guevara, M | 1 |
| Miguez, C | 1 |
| Cobas, S | 1 |
| Gorski, JC | 2 |
| Horlander, JC | 2 |
| Craven, R | 2 |
| Hoen, H | 2 |
| Maya, J | 2 |
| Brater, DC | 2 |
| Van Cauter, J | 1 |
| Lööf, L | 1 |
| Prytz, H | 1 |
| Söderlund, C | 1 |
| Wallerstedt, S | 1 |
| Planagumà, A | 1 |
| Titos, E | 1 |
| Masferrer, JL | 1 |
| Woerner, BM | 1 |
| Koki, AT | 1 |
| Altuna, R | 1 |
| Fuller, RK | 1 |
| Khambatta, PB | 1 |
| Gobezie, GC | 1 |
| Nicholson, G | 1 |
| Castagnolo, B | 1 |
| De Colibus, V | 1 |
| Napolitano, L | 1 |
| Aliperta, A | 1 |
| Caldarelli, G | 1 |
| Abignente, F | 1 |
| Blendis, LM | 2 |
| Greig, PD | 1 |
| Langer, B | 1 |
| Baigrie, RS | 1 |
| Ruse, J | 1 |
| Taylor, BR | 1 |
| Szabó, G | 1 |
| Serényi, P | 1 |
| Magyar, Z | 1 |
| Levy, M | 1 |
| Richard, C | 1 |
| Bakker-Grunwald, T | 1 |
| Zink, J | 1 |
| Greenway, CV | 1 |
| Vetter, H | 1 |
| Vetter, W | 1 |
| Beckerhoff, R | 1 |
| Glänzer, K | 1 |
| Hahn, C | 1 |
| Kolloch, R | 1 |
| Krück, F | 1 |
| Kutz, K | 1 |
| Witassek, F | 1 |
| Coltorti, M | 1 |
| Radaeli, E | 1 |
| Ciaccio, S | 1 |
| Corsini, R | 1 |
| Trebbi, R | 1 |
| Razis, DV | 1 |
| Athanasiou, A | 1 |
| Dadiotis, L | 1 |
| Bianchi Porre, G | 1 |
| Lazzaroni, M | 1 |
| Petrillo, M | 1 |
| Ehrly, AM | 1 |
| Van Waes, L | 1 |
| Schurgers, M | 1 |
| Demeulenaere, L | 1 |
| Acharya, SK | 1 |
| Balwinder, S | 1 |
| Padhee, AK | 1 |
| Nijhawan, S | 1 |
| Tandon, BN | 1 |
| Hagège, H | 1 |
| Ink, O | 1 |
| Ducreux, M | 1 |
| Pelletier, G | 1 |
| Buffet, C | 1 |
| Etienne, JP | 1 |
| Onuigbo, MA | 1 |
| Ozoh, JO | 1 |
| Nusiem, CA | 1 |
| Onyeagocha, AC | 1 |
| Nwaneri, O | 1 |
| Offodile, AA | 1 |
| Ijoma, CK | 1 |
| Jespersen, B | 1 |
| Jensen, L | 1 |
| Sørensen, SS | 1 |
| Pedersen, EB | 1 |
| el-Zayadi, A | 1 |
| Mohran, Z | 1 |
| Hasseeb, N | 1 |
| Nagy, N | 1 |
| Dabbous, H | 1 |
| Meacci, E | 1 |
| De Feo, ML | 1 |
| Wenk, E | 1 |
| Schölmerich, J | 1 |
| Goerg, KJ | 1 |
| Gerok, W | 1 |
| Leser, HG | 1 |
| Bardi, A | 5 |
| Orozco, R | 2 |
| Sapunar, J | 1 |
| Fernández, I | 2 |
| Mansurov, KhKh | 1 |
| Dustov, AD | 1 |
| Brunkhorst, R | 1 |
| Wrenger, E | 1 |
| Kühn, K | 1 |
| Schmidt, FW | 1 |
| Koch, K | 1 |
| Hattori, K | 1 |
| Yauchi, T | 1 |
| Minato, Y | 1 |
| Hasumura, Y | 1 |
| Takeuchi, J | 1 |
| Shiigai, T | 1 |
| Viver, J | 2 |
| Cabrera, J | 2 |
| Camps, J | 1 |
| Bruckstein, AH | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Sauerbruch, T | 1 |
| Fawthrop, F | 1 |
| O'Hare, JP | 1 |
| Millar, N | 1 |
| Weston, CF | 1 |
| Read, AE | 1 |
| Kandel, G | 1 |
| Diamant, NE | 1 |
| Daskalopoulos, G | 2 |
| Morgan, T | 1 |
| Harley, H | 1 |
| Reynolds, T | 1 |
| Zipser, RD | 2 |
| Pockros, PJ | 1 |
| Verbeeck, RK | 1 |
| Wilkinson, GR | 1 |
| Branch, RA | 1 |
| Decaux, G | 1 |
| Mols, P | 1 |
| Cauchie, P | 1 |
| Flamion, B | 1 |
| Delwiche, F | 1 |
| Kronborg, I | 1 |
| Katkov, W | 1 |
| Gonzalez, M | 1 |
| Talcott, J | 1 |
| Parlapiano, C | 1 |
| Paoletti, V | 1 |
| Pulido, M | 1 |
| Pupita, G | 1 |
| Gaggi, S | 1 |
| Sturniolo, GC | 1 |
| Farini, R | 1 |
| D'Angelo, A | 1 |
| Ossi, E | 1 |
| Senewiratne, B | 2 |
| Sherlock, S | 2 |
| Sonwalkar, AV | 1 |
| Wechalekar, MD | 1 |
| Wechalekar, DK | 1 |
| Waikar, SM | 1 |
| Bhala, BB | 1 |
| Bodin, F | 1 |
| Liguory, C | 1 |
| Capelle, P | 1 |
| Conte, M | 1 |
| Ventura, E | 1 |
| Zeneroli, ML | 1 |
| Ito, T | 1 |
| Kato, T | 1 |
| Yoshitoski, Y | 1 |
| Furrer, HU | 1 |
| Tönz, O | 1 |
| Tojo, S | 1 |
| Suzuki, H | 1 |
| Aach, R | 1 |
| Kissane, J | 1 |
| Lowenthal, DT | 1 |
| Shear, L | 1 |
| Dölle, W | 1 |
| Imler, M | 1 |
| Bockel, R | 1 |
| Peter, B | 1 |
| Kieny, R | 1 |
| Stahl, J | 1 |
| Perez-Stable, EC | 1 |
| Materson, BJ | 2 |
| Anderton, JL | 1 |
| Kincaid-Smith, P | 1 |
| Radó, JP | 1 |
| Marosi, J | 1 |
| Takó, J | 1 |
| Dévényi, I | 1 |
| Papadoyanakis, N | 1 |
| Darsinos, J | 1 |
| Alexandrou, K | 1 |
| Karli, J | 1 |
| Aleksić, IM | 1 |
| Azzi, E | 1 |
| Perraro, F | 1 |
| Walker, JG | 1 |
| Scott, A | 1 |
| Garcia, EM | 1 |
| Prata DJ da, C | 1 |
| de Carvalho, LV | 1 |
| Bemvenuti, GA | 1 |
| Job, JM | 1 |
| Cruz, J | 1 |
| Mattar, E | 1 |
| Cruz, HM | 1 |
| Schnack, H | 1 |
| Boivin, P | 2 |
| Fauvert, R | 2 |
| Eknoyan, G | 1 |
| Martinez-Maldonado, M | 1 |
| Yium, JJ | 1 |
| Suki, WN | 1 |
| Buligescu, L | 1 |
| Candiori, R | 1 |
| Bray, BV | 1 |
| Garrod, O | 1 |
| Gentili, G | 1 |
| Liberti, R | 1 |
| Bull, MB | 1 |
| Laragh, JH | 1 |
| Merino, I | 2 |
| Rendic, Y | 2 |
| Generini, G | 3 |
| Doerr, E | 1 |
| Plaza de los Reyes, M | 1 |
| Herrmann, GR | 1 |
| Ghiselli, RG | 1 |
| Steigmann, F | 3 |
| Mejicano, R | 1 |
| Branciari, C | 1 |
| Lauro, G | 1 |
| Menghini, G | 1 |
| Nuti, M | 1 |
| el Badry, A | 1 |
| el Safori, S | 1 |
| Oz, R | 2 |
| De Will, P | 1 |
| Dubin, A | 2 |
| Lieberman, FL | 1 |
| De Los Reyes, MP | 1 |
| Carrillo, E | 1 |
| Arroyo, JL | 1 |
| Bueno, J | 1 |
| Rivero, A | 1 |
| Lucas, I | 1 |
| Ortiz de Landazuri, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial[NCT01288794] | Phase 4 | 431 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Egyptian Cirrhotic Patients With Ascites[NCT04785755] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-30 | Completed | ||
| Immune-inflammatory and Metabolic Effects of High Dose Furosemide Plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects With Refractory Ascite[NCT02821377] | Phase 2 | 40 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| Phase 4 Study on the Comparison Between Combined Versus Sequential Diuretic Treatment of Moderate Ascites in Nonazotemic Patients With Cirrhosis[NCT00741663] | Phase 4 | 100 participants (Anticipated) | Interventional | 2005-04-30 | Completed | ||
| Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis[NCT05724485] | Phase 4 | 50 participants (Anticipated) | Interventional | 2023-04-01 | Not yet recruiting | ||
| Potential Role of Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Ascites in Cirrhotic Patients[NCT05999773] | 40 participants (Anticipated) | Observational | 2023-07-15 | Recruiting | |||
| The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients With Ascites and Activation of Sympathetic Nervous System: a Randomized Double-Blind Placebo Controlled Study.[NCT00356226] | 64 participants | Interventional | 2000-10-31 | Completed | |||
| Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)[NCT02832973] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Comparison of Success Rate and Complication Between Conventional Angiocatheter Versus New Anchoring Device (KARAHOC) Used for Paracentesis in Cirrhotic Patients With Ascites[NCT05578573] | 80 participants (Anticipated) | Interventional | 2022-01-17 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for furosemide and Ascites
| Article | Year |
|---|---|
[Supportive care for malignant ascites in palliative phase: Place of paracentesis and diuretics].
Topics: Aldosterone; Ascites; Capillary Permeability; Diuretics; Furosemide; Humans; Hypertension, Portal; P | 2015 |
Ascites: diagnosis and management.
Topics: Ascites; Ascitic Fluid; Cardiac Output; Diet, Sodium-Restricted; Disease Progression; Diuretics; Dru | 2009 |
Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites.
Topics: Ascites; Cardio-Renal Syndrome; Diuretics; Furosemide; Heart Failure; Humans; Infusions, Intravenous | 2011 |
Combined furosemide and human albumin treatment for diuretic-resistant edema.
Topics: Albumins; Ascites; Diuretics; Drug Therapy, Combination; Edema; Furosemide; Humans; Liver Cirrhosis; | 2003 |
[Refractory ascites: concept and therapeutic possibilities].
Topics: Ascites; Ascitic Fluid; Diet, Sodium-Restricted; Furosemide; Infusions, Parenteral; Peritoneovenous | 1983 |
Medical treatment of ascites in cirrhosis.
Topics: Ascites; Furosemide; Humans; Liver Cirrhosis; Spironolactone | 1993 |
Management of the patient with ascites.
Topics: Ascites; Bacterial Infections; Bed Rest; Diagnosis, Differential; Diuretics; Furosemide; Humans; Liv | 1987 |
A clinical view of recent advances in ascites.
Topics: Animals; Ascites; Ascitic Fluid; Bacterial Infections; Blood Volume; Body Water; Extracellular Space | 1986 |
Diuretic drug therapy of edema.
Topics: Ambulatory Care; Ascites; Body Weight; Chlorides; Diuresis; Diuretics; Edema; Ethacrynic Acid; Furos | 1971 |
Diuretics. II. Clinical considerations.
Topics: Administration, Oral; Aminophylline; Ascites; Calcium; Carbohydrate Metabolism; Carbonic Anhydrase I | 1971 |
50 trials available for furosemide and Ascites
| Article | Year |
|---|---|
Comparative Study of Slow Infusion versus Bolus Doses of Albumin and Furosemide Infusion to Mobilize Refractory Ascites in Decompensated Chronic Liver Disease.
Topics: Albumins; Ascites; Furosemide; Humans; Infusions, Intravenous; Liver Diseases; Nepal | 2020 |
Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weig | 2017 |
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
Topics: Aged; Albumins; Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Hyperkale | 2018 |
Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
Topics: Aged; Aged, 80 and over; Ascites; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2020 |
[Influence of non-sodium restricted diet with diuretics on plasma rennin, renal blood flow and in patients with cirrhotic ascites].
Topics: Ascites; Chymosin; Diet, Sodium-Restricted; Diuretics; Female; Furosemide; Hepatitis B; Humans; Live | 2013 |
High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Albumins; Ascites; Bilirubin; Creatinine; End | 2016 |
Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.
Topics: Adult; Aged; Aged, 80 and over; Ascites; Diuretics; Dose-Response Relationship, Drug; Female; Furose | 2009 |
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Diuretics; Dose-Response Relationship, Drug; Drug Administrati | 2010 |
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Diuretics; Dose-Response Relationship, Drug; Drug Administrati | 2010 |
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Diuretics; Dose-Response Relationship, Drug; Drug Administrati | 2010 |
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomised clinical trial.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Diuretics; Dose-Response Relationship, Drug; Drug Administrati | 2010 |
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Diuretics; Double-Blind Metho | 2010 |
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; | 2010 |
The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.
Topics: Administration, Oral; Ascites; Creatinine; Cross-Over Studies; Diuretics; Double-Blind Method; Femal | 2010 |
Clinical and neurohumoral response to posture, physical exercise, and ascites treatment in Child-Pugh C liver cirrhosis: randomized prospective trial.
Topics: Adult; Aged; Ascites; Bed Rest; Diuretics; Exercise; Female; Furosemide; Humans; Liver Cirrhosis; Ma | 2003 |
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Topics: Aged; Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Ma | 2003 |
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Topics: Aged; Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Ma | 2003 |
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Topics: Aged; Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Ma | 2003 |
Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.
Topics: Aged; Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Ma | 2003 |
Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites.
Topics: Ascites; Celecoxib; Dinoprostone; Double-Blind Method; Female; Furosemide; Glomerular Filtration Rat | 2005 |
The effects of treatment with octreotide, diuretics, or both on portal hemodynamics in nonazotemic cirrhotic patients with ascites.
Topics: Adult; Aged; Aldosterone; Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Gastroi | 2006 |
Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
Topics: Administration, Oral; Adult; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Ascite | 2006 |
Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system.
Topics: Angiotensins; Ascites; Clonidine; Diuretics; Drug Therapy, Combination; Female; Furosemide; Heart Ra | 2006 |
Studies on furosemide: an effective oral saludiuretic for bilharzial ascites.
Topics: Adolescent; Adult; Ascites; Body Weight; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle A | 1967 |
Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system.
Topics: Ascites; Clinical Trials as Topic; Diuresis; Dose-Response Relationship, Drug; Furosemide; Humans; L | 1983 |
Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial.
Topics: Amiloride; Ascites; Blood Chemical Analysis; Clinical Trials as Topic; Diet, Sodium-Restricted; Diur | 1983 |
Use of diuretics in the treatment of cirrhotic ascites.
Topics: Ascites; Bumetanide; Diuresis; Diuretics; Dose-Response Relationship, Drug; Furosemide; Humans; Kidn | 1983 |
Diuresis in the ascitic patient: a randomized controlled trial of three regimens.
Topics: Ascites; Body Weight; Clinical Trials as Topic; Drug Therapy, Combination; Female; Furosemide; Hepat | 1981 |
Treatment of patients with IVCS and gross oedema and ascites with diuretic combination and ACE-inhibitors: relation to baseline PRA and PAC.
Topics: Adult; Aged; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Ascites; Captopril; Diuretics; D | 1995 |
Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide.
Topics: Ascites; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Female; Furosemide; Hum | 1994 |
Effects of imidazole-salicylate on renal function and the diuretic action of furosemide in cirrhotic patients with ascites.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Ascites; Blood Platelets; Diuretics; Double-Bl | 1993 |
Advantages of the new loop diuretic torasemide over furosemide in patients with cirrhosis and ascites. A randomized, double blind cross-over trial.
Topics: Adult; Aged; Ascites; Diuretics; Double-Blind Method; Female; Furosemide; Humans; Liver Cirrhosis; M | 1993 |
Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content.
Topics: Ascites; Canrenoic Acid; Diet, Sodium-Restricted; Female; Furosemide; Humans; Liver Cirrhosis; Male; | 1993 |
Torasemide versus furosemide in cirrhosis: a long-term, double-blind, randomized clinical study.
Topics: Ascites; Diuretics; Double-Blind Method; Drug Therapy, Combination; Furosemide; Humans; Liver Cirrho | 1993 |
Torasemide in the treatment of patients with cirrhosis and ascites.
Topics: Adult; Aged; Ascites; Body Weight; Canrenoic Acid; Combined Modality Therapy; Diet, Sodium-Restricte | 1993 |
Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
Topics: Adult; Aged; Ascites; Diuretics; Drug Resistance; Female; Furosemide; Gas Chromatography-Mass Spectr | 1996 |
Therapeutic effects of diuretics and paracentesis on lung function in patients with non-alcoholic cirrhosis and tense ascites.
Topics: Aged; Ascites; Diuretics; Furosemide; Humans; Liver Cirrhosis; Lung; Male; Middle Aged; Paracentesis | 1997 |
[Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients].
Topics: Ascites; Diuretics; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Sulfonamides; To | 1997 |
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
Topics: Adult; Aged; Ascites; Bed Rest; Bilirubin; Blood Pressure; Blood Urea Nitrogen; Canrenoic Acid; Comb | 1999 |
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
Topics: Adult; Aged; Ascites; Bed Rest; Bilirubin; Blood Pressure; Blood Urea Nitrogen; Canrenoic Acid; Comb | 1999 |
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
Topics: Adult; Aged; Ascites; Bed Rest; Bilirubin; Blood Pressure; Blood Urea Nitrogen; Canrenoic Acid; Comb | 1999 |
Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial.
Topics: Adult; Aged; Ascites; Bed Rest; Bilirubin; Blood Pressure; Blood Urea Nitrogen; Canrenoic Acid; Comb | 1999 |
Long-term efficacy of torsemide compared with frusemide in cirrhotic patients with ascites.
Topics: Adult; Aged; Analysis of Variance; Ascites; Chi-Square Distribution; Diuretics; Drug Administration | 2001 |
Effect of albumin-furosemide mixtures on response to furosemide in cirrhotic patients with ascites.
Topics: Adult; Albumins; Ascites; Cross-Over Studies; Diuretics; Female; Furosemide; Humans; Liver Cirrhosis | 2001 |
An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.
Topics: Ascites; Body Weight; Clinical Trials as Topic; Diuretics; Furosemide; Humans; Liver Cirrhosis; Plas | 1977 |
Treatment of fluid retention in cirrhosis: a comparison of bumetanide and frusemide.
Topics: Adult; Aged; Ascites; Bumetanide; Clinical Trials as Topic; Diuretics; Edema; Female; Furosemide; Hu | 1977 |
[Clinical evaluation of the use of diuretics in the ascitic phase of hepatic cirrhosis].
Topics: Acute Disease; Adult; Aged; Amiloride; Ascites; Clinical Trials as Topic; Diuretics; Drug Evaluation | 1977 |
[Letter: Ascrtogenicliver cirrhosis. Effect of amiloride on water-electrolytemetabolsim].
Topics: Amiloride; Ascites; Chlorides; Clinical Trials as Topic; Furosemide; Humans; Hydrochlorothiazide; Hy | 1975 |
Large volume paracentesis and intravenous dextran to treat tense ascites.
Topics: Adult; Ascites; Combined Modality Therapy; Dextrans; Drainage; Drug Administration Schedule; Female; | 1992 |
[Treatment of ascites in patients with liver cirrhosis without neither hyponatremia nor renal insufficiency. Results of a randomized study comparing diuretics and punctures compensated by albumin].
Topics: Aged; Albumins; Ascites; Combined Modality Therapy; Drug Therapy, Combination; Female; Furosemide; H | 1992 |
Short-term course of corticosteroids in the treatment of resistant ascites complicating schistosomal liver disease.
Topics: Adolescent; Adult; Aged; Ascites; Chronic Disease; Diuresis; Drug Therapy, Combination; Female; Furo | 1991 |
Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study.
Topics: Ascites; Diuretics; Double-Blind Method; Furosemide; Humans; Liver Cirrhosis; Sulfonamides; Torsemid | 1991 |
Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion.
Topics: Adult; Aged; Ascites; Creatinine; Diuretics; Drug Therapy, Combination; Female; Furosemide; Glomerul | 1990 |
Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites.
Topics: Ascites; Clinical Trials as Topic; Diuretics; Female; Follow-Up Studies; Furosemide; Humans; Liver C | 1985 |
Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study.
Topics: Albumins; Ascites; Clinical Trials as Topic; Diuretics; Drainage; Female; Follow-Up Studies; Furosem | 1987 |
More on the comparison of paracentesis versus diuretics in the treatment of patients with tense ascites.
Topics: Ascites; Drug Therapy, Combination; Furosemide; Humans; Punctures; Spironolactone | 1988 |
Sulindac and indomethacin suppress the diuretic action of furosemide in patients with cirrhosis and ascites: evidence that sulindac affects renal prostaglandins.
Topics: Anti-Inflammatory Agents; Ascites; Clinical Trials as Topic; Creatinine; Dinoprostone; Diuresis; Dru | 1985 |
[Controlled clinical trial of the association of furosemide and triamterene].
Topics: Ascites; Diuresis; Edema; Electrolytes; Furosemide; Heart Failure; Humans; Liver Cirrhosis; Triamter | 1971 |
[Modern diuretic therapy in chronic liver diseases].
Topics: Adult; Aged; Ascites; Clinical Trials as Topic; Diuretics; Female; Furosemide; Humans; Hydrochloroth | 1965 |
132 other studies available for furosemide and Ascites
| Article | Year |
|---|---|
Effects of adding hypertonic saline solutions and/or etilefrine to standard diuretics therapy in cirrhotic patients with ascites.
Topics: Aldosterone; Ascites; Biomarkers; C-Reactive Protein; Creatinine; Diuretics; Etilefrine; Furosemide; | 2022 |
Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Femal | 2020 |
Finger clubbing and cirrhosis in a sarcoidosis patient.
Topics: Administration, Oral; Anti-Inflammatory Agents; Ascites; Diuretics; Female; Furosemide; Humans; Hype | 2019 |
Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glucose Metabolism, Liver Function, Ascites, and Hemodynamics in a Mouse Model of Nonalcoholic Steatohepatitis and Type 2 Diabetes.
Topics: Animals; Ascites; Benzhydryl Compounds; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diseas | 2020 |
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weig | 2017 |
Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Furosemide; Humans; Kaplan-Meier E | 2019 |
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Ascitic Fluid; Diuretic | 2019 |
Ascites in patients with cirrhosis.
Topics: Abdominal Pain; Aged; Analgesics, Opioid; Ascites; Catheters, Indwelling; Diet, Sodium-Restricted; D | 2013 |
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Drug Administration Sch | 2015 |
The failing heart: a bad case of the 'flu'.
Topics: Ascites; Cardio-Renal Syndrome; Cardiomyopathy, Dilated; Diagnosis, Differential; Diuretics; Echocar | 2015 |
A common autoimmune disease with rare organ involvement.
Topics: Adult; Ascites; Bronchoscopy; Diuretics; Female; Furosemide; Glucocorticoids; Humans; Laparotomy; Ly | 2015 |
Cirrhosis complications: keeping them under control.
Topics: Antihypertensive Agents; Ascites; Diuretics; Furosemide; Hemorrhage; Hepatic Encephalopathy; Humans; | 2015 |
Pathogenesis of solute-free water retention in experimental ascitic cirrhosis: is vasopressin the only culprit?
Topics: Animals; Ascites; Canrenoic Acid; Diuretics; Furosemide; Guanfacine; Hyponatremia; Liver Cirrhosis, | 2016 |
Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine.
Topics: Adrenergic Agonists; Animals; Ascites; Canrenoic Acid; Clonidine; Diuretics; Drug Synergism; Fibrosi | 2016 |
Immune-Inflammatory and Metabolic Effects of High Dose Furosemide plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects with Refractory Ascites.
Topics: Administration, Intravenous; Aged; Ascites; Biomarkers; Cytokines; Diuretics; Female; Furosemide; Hu | 2016 |
Liver: diuretic agents for ascites: joining forces from the start?
Topics: Ascites; Canrenoic Acid; Drug Therapy, Combination; Furosemide; Humans; Liver Cirrhosis; Mineralocor | 2010 |
Oral furosemide-induced natriuresis: a potential method for identifying cirrhotic patients with refractory ascites.
Topics: Administration, Oral; Ascites; Diuretics; Furosemide; Hepatorenal Syndrome; Humans; Infusions, Intra | 2010 |
Refractory ascites: can it be defined only by the response to furosemide and spironolactone?
Topics: Ascites; Diuretics; Furosemide; Glomerular Filtration Rate; Hepatorenal Syndrome; Humans; Liver Cirr | 2010 |
Midodrine and furosemide-induced natriuresis in cirrhotics with ascites.
Topics: Ascites; Furosemide; Humans; Liver Cirrhosis; Midodrine; Natriuresis | 2011 |
Continuous furosemide infusion in the management of ascites.
Topics: Adult; Aged; Ascites; Disease Management; Diuretics; Electronic Health Records; Female; Furosemide; | 2012 |
EFFECT OF A NEW ORAL DIURETIC--FURSEMIDE ON BILHARZIAL CIRRHOSIS WITH ASCITES.
Topics: Animals; Ascites; Diuretics; Drug Therapy; Furosemide; Humans; Liver Cirrhosis; Schistosoma; Schisto | 1964 |
[CLINICAL EXPERIENCES WITH A NEW NON-MERCURIAL DIURETIC: 4-CHLORO-N-(2-FURYL-METHYL)-5-SULFAMYL-ANTHRANILIC ACID OR FUROSEMIDE].
Topics: Ascites; Diuretics; Edema; Furosemide; Heart Diseases; Humans; Liver Cirrhosis; ortho-Aminobenzoates | 1965 |
[CLINICAL RESEARCH ON THE USE OF 4-CHLORO-N-(2-FURYLMETHYL)-5-SULFAMYL-ANTHRANILIC ACID].
Topics: Ascites; Diuretics; Edema; Furosemide; Heart Failure; Humans; Liver Cirrhosis; ortho-Aminobenzoates | 1965 |
[ON CLINICAL APPLICATIONS OF FUROSEMIDE].
Topics: Ascites; Diuretics; Edema; Furosemide; Humans; Neoplasms | 1965 |
[ON CLINICAL APPLICATIONS OF FUROSEMIDE].
Topics: Ascites; Diuretics; Edema; Furosemide; Humans; Neoplasms | 1965 |
Scintigraphic findings in a case of bilateral urinomas and ascites secondary to posterior urethral valves.
Topics: Ascites; Diuretics; Furosemide; Humans; Infant, Newborn; Male; Radioisotope Renography; Radiopharmac | 2003 |
[The significance of urine sodium measurement after furosemide administration in diuretics-unresponsive patients with liver cirrhosis].
Topics: Adult; Aged; Ascites; Diuretics; Female; Furosemide; Humans; Infusions, Intravenous; Liver Cirrhosis | 2003 |
Budd-Chiari syndrome in a young patient with celiac sprue: a case report.
Topics: Ascites; Budd-Chiari Syndrome; Celiac Disease; Diet, Gluten-Free; Diuretics; Duodenum; Endoscopy, Di | 2003 |
Subcutaneous furosemide.
Topics: Ascites; Diuretics; Furosemide; Heart Failure; Hospice Care; Humans; Injections, Subcutaneous; Treat | 2004 |
A rare cause of diuretic refractory ascites.
Topics: Ascites; Constriction, Pathologic; Cysts; Diuretics; Female; Furosemide; Humans; Liver Diseases; Mag | 2006 |
The significance of the furosemide test for predicting ascites control by diuretics in cirrhotics: a comparison with volume expansion and octreotide infusion.
Topics: Aged; Ascites; Diuretics; Female; Furosemide; Gastrointestinal Agents; Glomerular Filtration Rate; H | 2006 |
Massive ascites and hydrothorax after leuprolide acetate administration in a down-regulated woman undergoing assisted reproduction.
Topics: Adult; Ascites; Down-Regulation; Female; Furosemide; Humans; Hydrothorax; Infertility, Female; Leupr | 2007 |
Characteristics of ascitic fluid in cardiac ascites.
Topics: Aged; Albumins; Ascites; Ascitic Fluid; Diagnosis, Differential; Diuretics; Erythrocyte Count; Exuda | 2007 |
Pharmacologic approaches for volume excess in acute kidney injury (AKI).
Topics: Acute Kidney Injury; Ascites; Bumetanide; Diuretics; Fluid Therapy; Furosemide; Heart Failure; Hepat | 2008 |
Diuretics.
Topics: Aldosterone; Ascites; Chlorothiazide; Diuretics; Edema; Ethacrynic Acid; Furosemide; Humans; Organom | 1967 |
[Acute fatty liver in pregnancy with consumption coagulopathy].
Topics: Acute Disease; Adult; Ampicillin; Ascites; Disseminated Intravascular Coagulation; Electrolytes; Fat | 1983 |
[Observations on a case of liver cirrhosis in its terminal phase].
Topics: Ascites; Bilirubin; Blood Glucose; Furosemide; Humans; Insulin; Liver Cirrhosis; Male; Middle Aged; | 1984 |
Intravenous infusion of frusemide as treatment for ascites in malignant disease.
Topics: Adult; Aged; Ascites; Female; Furosemide; Humans; Infusions, Parenteral; Middle Aged; Neoplasms | 1984 |
Propranolol in the treatment of cirrhotic ascites.
Topics: Ascites; Furosemide; Humans; Liver Cirrhosis; Natriuresis; Propranolol; Triamterene | 1984 |
[Therapy of ascites by peritoneo-venous shunt].
Topics: Ascites; Diet, Sodium-Restricted; Equipment Failure; Furosemide; Hemorrhage; Humans; Life Expectancy | 1984 |
Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
Topics: Adult; Aged; Ascites; Diuresis; Female; Furosemide; Humans; Kinetics; Liver Cirrhosis; Male; Middle | 1982 |
[Treatment of irreducible ascites of cirrhotic patients with peritoneo-jugular shunt].
Topics: Ascites; Breathing Exercises; Diet, Sodium-Restricted; Female; Furosemide; Humans; Jugular Veins; Li | 1982 |
Increased transvascular escape rate and lymph drainage of albumin in pigs during intravenous diuretic medication. Relations to treatment in man and transport mechanisms.
Topics: Albumins; Animals; Ascites; Biological Transport; Capillary Permeability; Edema; Female; Furosemide; | 1982 |
[Clinical program of therapy for ascitic edema in liver disease].
Topics: Ascites; Diuresis; Edema; Furosemide; Humans; Liver Cirrhosis | 1982 |
Hemodynamics of LeVeen shunt pulmonary edema.
Topics: Ascites; Cardiac Output; Diuresis; Female; Furosemide; Hemodynamics; Humans; Male; Middle Aged; Peri | 1981 |
[Furosemide and metolazone: a highly effective diuretic combination].
Topics: Ascites; Body Weight; Diuresis; Diuretics; Drug Combinations; Edema, Cardiac; Female; Furosemide; He | 1980 |
Furosemide kinetics in patients with hepatic cirrhosis with ascites.
Topics: Adult; Aged; Ascites; Diuresis; Furosemide; Humans; Kinetics; Liver Cirrhosis; Male; Middle Aged | 1981 |
Furosemide disposition in cirrhotic patients.
Topics: Administration, Oral; Ascites; Biological Availability; Furosemide; Half-Life; Humans; Infusions, Pa | 1981 |
Treatment of hepatorenal syndrome.
Topics: Adult; Ascites; Ascitic Fluid; Creatine; Furosemide; Humans; Infusions, Parenteral; Kidney Diseases; | 1980 |
Drug therapy of ascites.
Topics: Ascites; Diuretics; Ethacrynic Acid; Furosemide; Humans; Hydrochlorothiazide; Sodium Chloride Sympor | 1981 |
Ascites formation and dynamics in cirrhotic patients.
Topics: Ascites; Diuretics; Furosemide; Humans; Liver Cirrhosis | 1995 |
Ascites free-water dynamics in decompensated cirrhosis: effects of acute and chronic frusemide treatment.
Topics: Abdomen; Administration, Oral; Adult; Aged; Aged, 80 and over; Ascites; Body Water; Body Weight; Fem | 1995 |
Effects of KW-3902, an adenosine A1-receptor antagonist, on ascites volume in puromycin aminonucleoside (PAN)-induced nephrotic rats.
Topics: Animals; Ascites; Diuretics; Edema; Furosemide; Male; Nephrosis; Purinergic P1 Receptor Antagonists; | 1995 |
The intraabdominal pressure in decompensated cirrhosis: relationship with ascites volume and turn-over.
Topics: Adult; Aged; Aged, 80 and over; Ascites; Female; Furosemide; Humans; Hydrostatic Pressure; Liver Cir | 1994 |
Sequential nephron blockade breaks resistance to diuretics in edematous states.
Topics: Acetazolamide; Adult; Ascites; Diuresis; Diuretics; Edema; Female; Furosemide; Heart Failure; Humans | 1997 |
Predictive factors influencing the therapeutic response to diuretic treatment of ascites in nonazotemic cirrhotic patients.
Topics: Ascites; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis, Alcoholi | 1998 |
Effects of recombinant human serum albumin on ascites in rats with puromycin aminonucleoside-induced nephropathy.
Topics: Animals; Ascites; Disease Models, Animal; Diuretics; Drug Evaluation, Preclinical; Furosemide; Human | 1998 |
Intravenous albumin with diuretics: protean lessons to be learnt?
Topics: Ascites; Bed Rest; Canrenoic Acid; Diuretics; Furosemide; Humans; Infusions, Intravenous; Liver Cirr | 1999 |
Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites.
Topics: Ascites; Diuretics; Drug Resistance; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; | 2001 |
Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients.
Topics: Adult; Albumins; Ascites; Diuretics; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; | 2001 |
[Biological factors influencing response to diuretics in patients with cirrhosis and ascites].
Topics: Aldosterone; Ascites; Diuretics; Female; Furosemide; Glomerular Filtration Rate; Humans; Hyperkalemi | 2001 |
[Therapeutic program for ascites. Recommendations from the Swedish Society of Gastroenterology and Gastrointestinal Endoscopy].
Topics: Ascites; Contraindications; Diuretics; Furosemide; Humans; Liver Cirrhosis; Paracentesis; Peritoneov | 2001 |
Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.
Topics: Animals; Ascites; Blotting, Western; Carbon Tetrachloride Poisoning; Celecoxib; Cyclooxygenase 1; Cy | 2002 |
The renal and hemodynamic effects of the peritoneovenous shunt for intractable hepatic ascites.
Topics: Adult; Aged; Aldosterone; Ascites; Body Weight; Budd-Chiari Syndrome; Cardiac Output; Diuresis; Drai | 1979 |
The effect of diuretic drugs on lymph flow in experimental ascites.
Topics: Alkylmercury Compounds; Animals; Ascites; Blood Pressure; Diuretics; Dogs; Ethacrynic Acid; Female; | 1979 |
Mobilization of ascites in cirrhotic dogs following furosemide or mannitol diuresis.
Topics: Animals; Ascites; Central Venous Pressure; Dimethylnitrosamine; Diuresis; Dogs; Extracellular Space; | 1978 |
Effect of anions of potassium self-exchange in ascites tumor cells.
Topics: Animals; Anions; Ascites; Biological Transport; Chlorides; Furosemide; Mice; Nitrates; Ouabain; Pota | 1978 |
Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis.
Topics: Absorption; Animals; Ascites; Ascitic Fluid; Cats; Diuresis; Furosemide; Pressure; Proteins | 1977 |
[Aldosterone and renin in liver cirrhosis with ascites].
Topics: Aldosterone; Ascites; Furosemide; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Renin; Spiron | 1977 |
[Therapeutic report on an injectable aldosterone antagonist (K-canrenoate) in states of water-salf retention].
Topics: Adult; Aged; Ascites; Canrenoic Acid; Drug Evaluation; Drug Therapy, Combination; Edema; Ethacrynic | 1976 |
Diuretics in malignant effusions and edemas of generalized cancer.
Topics: Ascites; Body Weight; Bumetanide; Diuretics; Drinking; Edema; Furosemide; Humans; Neoplasms; Pleuris | 1976 |
[Irrigation of edemas and thrombosis].
Topics: Ascites; Blood Viscosity; Diuretics; Edema, Cardiac; Furosemide; Hematocrit; Humans; Thrombosis | 1975 |
The Rhodiascit system--individual response to reinfusion possibly related to angiotensin sensitivity: preliminary results.
Topics: Adult; Aged; Ascites; Ascitic Fluid; Diuresis; Furosemide; Humans; Infusions, Parenteral; Middle Age | 1975 |
Combined ascitic--fluid and furosemide infusion: a therapeutic option for massive diuretic-resistant ascites and severe oliguria of hepatic cirrhosis.
Topics: Adult; Ascites; Ascitic Fluid; Furosemide; Humans; Injections, Intraperitoneal; Injections, Intraven | 1991 |
Atrial natriuretic factor, cyclic 3',5'-guanosine monophosphate and prostaglandin E2 in liver cirrhosis: relation to blood volume and changes in blood volume after furosemide.
Topics: Adult; Aged; Ascites; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Dinoprostone; Diuresis; F | 1990 |
[Hepatic cirrhosis with refractory ascitis and changes in renal function: effects of the infusion of fresh plasma and furosemide].
Topics: Ascites; Female; Furosemide; Humans; Infusions, Intravenous; Kidney; Liver Cirrhosis; Male; Plasma | 1989 |
[Effect of furosemide on the renal prostaglandin system in liver cirrhosis with ascites].
Topics: Adult; Ascites; Circadian Rhythm; Dinoprost; Dinoprostone; Diuresis; Female; Furosemide; Humans; Kid | 1989 |
[Effect of captopril therapy on sodium and water excretion in patients with liver cirrhosis and ascites].
Topics: Adult; Aged; Ascites; Blood Pressure; Captopril; Diuresis; Diuretics; Dose-Response Relationship, Dr | 1989 |
A lithium clearance study of sodium reabsorption at the proximal tubule in liver cirrhosis with ascites.
Topics: Absorption; Ascites; Creatinine; Female; Furosemide; Humans; Kidney Tubules, Proximal; Lithium; Live | 1989 |
Ascites kinetics in cirrhosis: effects of rapid volume expansion and diuretic administration.
Topics: Albumins; Ascites; Ascitic Fluid; Diuresis; Furosemide; Humans; Kinetics; Liver Cirrhosis; Plasma Vo | 1988 |
[Has treatment of ascites changed?].
Topics: Ascites; Drainage; Drug Therapy, Combination; Furosemide; Humans; Spironolactone | 1988 |
Combined use of water immersion and frusemide in treatment of resistant ascites in liver cirrhosis.
Topics: Adult; Ascites; Combined Modality Therapy; Furosemide; Humans; Immersion; Liver Cirrhosis; Male | 1987 |
The use of peritoneovenous shunting in unravelling the pathogenesis of ascites in cirrhosis.
Topics: Aldosterone; Ascites; Creatinine; Furosemide; Humans; Kidney; Liver Cirrhosis; Natriuresis; p-Aminoh | 1986 |
Immediate effects of furosemide on renal hemodynamics in chronic liver disease with ascites.
Topics: Ascites; Blood Pressure; Chronic Disease; Furosemide; Hemodynamics; Humans; Inulin; Kidney; Liver Di | 1987 |
Refractory ascites: definition and mechanism.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Ascites; Diet, Sodium-Restricted; Diuretics; Drainage; Drug | 1987 |
Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema.
Topics: Amiloride; Ascites; Body Weight; Chronic Disease; Diuresis; Edema; Electrolytes; Furosemide; Humans; | 1986 |
Furosemide kinetics and dynamics in patients with cirrhosis.
Topics: Adult; Ascites; Biological Availability; Diuresis; Furosemide; Half-Life; Humans; Injections, Intrav | 1986 |
'Diuretic-resistant' ascites. Observations on pathogenesis.
Topics: Ascites; Diuretics; Drug Resistance; Furosemide; Humans; Hydrostatic Pressure; Kidney; Liver; Liver | 1986 |
Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea.
Topics: Adult; Ascites; Body Weight; Creatinine; Drug Therapy, Combination; Edema; Furosemide; Humans; Hypon | 1986 |
Girth increase, sudden pain in a cardiac patient.
Topics: Ascites; Colonic Neoplasms; Female; Furosemide; Heart Failure; Heart Valve Prosthesis; Humans; Middl | 1985 |
[Reasons for diuretic therapy of cirrhotic ascites].
Topics: Ascites; Bed Rest; Benzothiadiazines; Diet, Sodium-Restricted; Diuretics; Drug Therapy, Combination; | 1985 |
Clinical pharmacology of loop diuretics: a comparative study.
Topics: Adult; Ascites; Blood Pressure; Body Weight; Bumetanide; Diuresis; Diuretics; Electrolytes; Female; | 1985 |
Letter: Treatment of ascites.
Topics: Adult; Aged; Ascites; Ascitic Fluid; Diuresis; Furosemide; Humans; Infusions, Parenteral; Injections | 1974 |
Amiloride ('MK 870') in patients with ascites due to cirrhosis of the liver.
Topics: Adult; Ascites; Bicarbonates; Creatinine; Diuretics; Ethacrynic Acid; Furosemide; Guanidines; Humans | 1968 |
A new approach for refractory oedema--pharmacological paracentesis.
Topics: Ascites; Drug Administration Schedule; Edema; Electrolytes; Furosemide; Humans; Hypertension, Portal | 1973 |
[Disorders of water-electrolyte metabolism associated with decompensated cirrhosis. The danger of various therapeutic drugs].
Topics: Acute Kidney Injury; Adult; Aged; Ascites; Blood Transfusion; Blood Urea Nitrogen; Blood Volume Dete | 1968 |
[The salidiuretic interaction of angiotensin II and furosemide in ascitogenic hepatic cirrhosis].
Topics: Angiotensin II; Ascites; Diuresis; Drug Interactions; Electrolytes; Female; Furosemide; Humans; Kidn | 1969 |
Response of plasma aldosterone to postural change, diuretica, angiotensin II, sodium restriction or loading and prostaglandin.
Topics: Adrenocortical Hyperfunction; Aldosterone; Angiotensin II; Ascites; Cushing Syndrome; Diet; Diet, So | 1973 |
[Acute hemolysis in morbus Wilson (author's transl)].
Topics: Adolescent; Adult; Anemia, Hemolytic; Ascites; Bilirubin; Blood Coagulation Tests; Blood Protein Ele | 1974 |
[My prescription of diuretics].
Topics: Adolescent; Aged; Ascites; Diuretics; Edema, Cardiac; Female; Furosemide; Heart Failure; Humans; Kid | 1974 |
Hypoproteinemia, splenomegaly, ascites and disseminated histoplasmosis.
Topics: Amphotericin B; Ascites; Furosemide; Histoplasmosis; Hodgkin Disease; Humans; Hypoproteinemia; Male; | 1973 |
Use of a new diuretic agent (metolazone) in patients with edema and ascites.
Topics: Ascites; Blood Urea Nitrogen; Creatinine; Diuretics; Edema; Furosemide; Humans; Injections, Intraven | 1973 |
[Effect of furosemide combined with reinfusion of ascitic fluid in hepatic cirrhosis with refractory ascites and changes in renal function].
Topics: Ascites; Ascitic Fluid; Evaluation Studies as Topic; Furosemide; Humans; Kidney Failure, Chronic; Ki | 1973 |
[Pathogenesis and therapy of ascites in liver cirrhosis].
Topics: Acid-Base Equilibrium; Alkalosis; Ascites; Deficiency Diseases; Diet; Diuresis; Diuretics; Furosemid | 1966 |
[Importance of hyperammoniemia of the renal origin in the pathogenesis of hepatic coma released in cirrhotic patients by diuretics generating hypokaliemia].
Topics: Acetazolamide; Acid-Base Equilibrium; Alkalosis; Ammonia; Ascites; Chlorides; Chlorthalidone; Edema; | 1969 |
Hyperkalemic intermittent paralysis associated with spironolactone in a patient with cardiac cirrhosis.
Topics: Acetazolamide; Adult; Aldosterone; Ascites; Female; Furosemide; Heart Failure; Heart Valve Diseases; | 1968 |
High doses of spironolactone in the treatment of liver cirrhosis with ascites.
Topics: Adult; Aged; Ascites; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Prednisolone; Spironol | 1972 |
[Myxedematous ascites].
Topics: Ascites; Female; Furosemide; Humans; Middle Aged; Myxedema; Thyroid Hormones; Water-Electrolyte Bala | 1972 |
Generalized burning paresthesia due to intravenous furosemide.
Topics: Ascites; Furosemide; Humans; Injections, Intravenous; Liver Cirrhosis; Male; Middle Aged; Paresthesi | 1971 |
The complications of diuretic therapy in patients with cirrhosis.
Topics: Alkalosis; Ascites; Blood Urea Nitrogen; Chlorothiazide; Ethacrynic Acid; Furosemide; Hepatic Enceph | 1966 |
[Clinical experimentation with furosemide].
Topics: Ascites; Female; Furosemide; Heart Failure; Humans; Male | 1966 |
[Management of hepatic ascites using Fursemide].
Topics: Adult; Ascites; Female; Furosemide; Humans; Liver Cirrhosis; Male; Methods; Middle Aged | 1968 |
[Triamterene-frusemide combination in edematous patients].
Topics: Adult; Ascites; Body Weight; Diuresis; Diuretics; Drug Synergism; Edema; Electrolytes; Female; Furos | 1970 |
[Experience in the treatment of water-salt retentions in cirrhosis by the antialdosterone 11614 R.P].
Topics: 17-Hydroxycorticosteroids; Adult; Androstanes; Ascites; Diuresis; Edema; Female; Furosemide; Humans; | 1969 |
Combined ascitic-fluid and furosemide infusion in the management of ascites.
Topics: Adult; Aged; Ascites; Ascitic Fluid; Bilirubin; Blood Proteins; Blood Urea Nitrogen; Body Weight; Cr | 1970 |
[Modern diuretics in the treatment of ascites caused by hepatic cirrhosis].
Topics: Adult; Aged; Aldosterone; Ascites; Diuretics; Female; Furosemide; Humans; Hydrochlorothiazide; Liver | 1970 |
Myxoedematous ascites.
Topics: Aged; Ascites; Female; Furosemide; Hemorrhoids; Humans; Myxedema; Thyroxine; Uterine Prolapse | 1970 |
[Clinical study of the use of "Spirolang" 50].
Topics: Adult; Aged; Ascites; Chronic Disease; Digitalis Glycosides; Diuresis; Electrolytes; Ethacrynic Acid | 1971 |
Amiloride. A potassium-sparing natriuretic agent.
Topics: Acetazolamide; Aldosterone; Ammonia; Ascites; Bicarbonates; Blood Pressure; Chlorides; Chlorothiazid | 1968 |
[Urinary excretion of magnesium in patients with liver cirrhosis treated with oral diuretics. Its variation through vasopressin].
Topics: Adult; Ascites; Diuretics; Ethacrynic Acid; Furosemide; Humans; Liver Cirrhosis; Magnesium; Male; Th | 1968 |
[Effects of furosemide on diuresis and salt diuresis, blood electrolytes concentrations in various aspects of renal function in liver cirrhotic patients with ascites].
Topics: Ascites; Diuresis; Electrolytes; Furosemide; Humans; Kidney; Liver Cirrhosis; Sodium Chloride | 1968 |
Clinical experience with furosemide.
Topics: Adolescent; Adult; Aged; Ascites; Carbon Dioxide; Chlorides; Diabetes Complications; Diuresis; Edema | 1968 |
The impact of diuretics on chronic liver disease.
Topics: Alcoholism; Ascites; Chlorothiazide; Diet Therapy; Diuretics; Ethacrynic Acid; Furosemide; Humans; L | 1969 |
[Clinical observations on the efficacy of a new diuretic: furosemide].
Topics: Adult; Aged; Ascites; Diabetes Insipidus; Diuretics; Furosemide; Heart Failure; Humans; Liver Cirrho | 1965 |
[Clinical trials of a new salidiuretic, furosemide, in the treatment of cirrhotic ascites. Early results].
Topics: Ascites; Diuretics; Furosemide; Humans | 1965 |
[Furosemide in treatment of the edema syndrome in cirrhotics].
Topics: Ascites; Diuretics; Furosemide; Humans; Liver Cirrhosis | 1965 |
[A new diuretic: Furosemide. Its effect on bilahariasis-cirrhosis with ascites].
Topics: Ascites; Diuretics; Furosemide; Liver Cirrhosis; Schistosomiasis | 1965 |
Furosemide therapy in "intractable ascites".
Topics: Adult; Aged; Ascites; Edema; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Water-E | 1966 |
Renal failure with cirrhosis. Observations on the role of diuretics.
Topics: Acute Kidney Injury; Aminohippuric Acids; Ascites; Blood; Blood Volume; Creatine; Diuretics; Ethacry | 1966 |
Newer diuretics in the treatment of cardiac or hepatic disease in elderly patients.
Topics: Ascites; Benzothiadiazines; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cardiovascular Diseases | 1966 |
[Effect of furosemide on liver cirrhosis patients with ascites].
Topics: Ascites; Chlorides; Furosemide; Glomerular Filtration Rate; Humans; Liver Cirrhosis; Natriuresis; Po | 1966 |
[Treatment of ascites in hepatic cirrhosis].
Topics: Acetazolamide; Adult; Aged; Ascites; Benzothiadiazines; Furosemide; Humans; Liver Cirrhosis; Male; M | 1966 |